In addition to this spectrum of oncogenic KRAS mutations, evaluation of specific pro- or anti-tumourigenic roles for the wild-type RAS proteins in the context of oncogenic RAS across cancer types has been controversial. The gene discussed is KRAS; the disease is cancer.